Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1502-1507

  Hall II, Ronald G ^a,b   Swancutt, Mark A ^b   Meek, Claudia ^a   Leff, Richard D ^a   Gumbo, Tawanda ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; COLOR VISION; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG HALF LIFE; EPISTAXIS; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; LEAN BODY WEIGHT; MALE; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; VISUAL ACUITY; VISUAL FIELD DEFECT;

ADMINISTRATION, ORAL; ADULT; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; BODY MASS INDEX; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; ETHAMBUTOL; FEMALE; HUMANS; MALE; MIDDLE AGED; OBESITY; OBESITY, MORBID; OVERWEIGHT; PROSPECTIVE STUDIES; SOFTWARE;

EID: 84857183281     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05623-11     Document Type: Article

References (46)

1. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans. Automat. Contr. 19:716-723.
2. Alffenaar JW, van der Werf TS. 2010. Dosing ethambutol in obese patients. Antimicrob. Agents Chemother. 54:4044.
3. Baker SS, Baker RD, Liu W, Nowak NJ, Zhu L. 2010. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One 5:e9570.
4. Blumberg HM, et al. 2003. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167:603-662.
5. Center for Drug Evaluation Research. 1999. Guidance for industry. Population pharmacokinetics. CP 1. Food and Drug Administration, Rockville, MD.
6. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41.
7. D'Argenio DZ, Schumitzky A, Wang X. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
8. Deshpande D, Srivastava S, Meek C, Leff R, Gumbo T. 2010. Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. Antimicrob. Agents Chemother. 54:1728-1733.
9. Filozof C, Gonzalez C, Sereday M, Mazza C, Braguinsky J. 2001. Obesity prevalence and trends in Latin-American countries. Obes. Rev. 2:99-106. (Pubitemid 33755919)
10. Flegal KM, Carroll MD, Ogden CL, Curtin LR. 2010. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303:235-241.
11. Griffith DE. 2007. Therapy of nontuberculous mycobacterial disease. Curr. Opin. Infect. Dis. 20:198-203. (Pubitemid 46340804)
12. Griffith DE, et al. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 175:367-416.
13. Griffith DE, Brown BA, Cegielski P, Murphy DT, Wallace RJ, Jr. 2000. Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. Clin. Infect. Dis. 30:288-292. (Pubitemid 30131535)
14. Griffith DE, et al. 2005. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 172:250-253. (Pubitemid 40981202)
15. Gumbo T. 2010. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy, p 1549-1570. In Brunton LL, Chabner B, Knollmann B (ed), Goodman & Gilman's The pharmacological basis of therapeutics, 12th ed. McGraw Hill Medical, New York, NY.
16. Gumbo T, et al. 2008. Population pharmacokinetics of micafungin in adult patients. Diagn. Microbiol. Infect. Dis. 60:329-331. (Pubitemid 351253603)
17. Hall RG, Swancutt MA, Gumbo T. 2011. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob. Agents Chemother. 55:5107-5112.
18. Hasenbosch RE, et al. 2008. Ethambutol-induced optical neuropathy: risk of overdosing in obese subjects. Int. J. Tuberc. Lung Dis. 12:967-971.
19. Hope WW, et al. 2007. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob. Agents Chemother. 51:3714-3719. (Pubitemid 47519363)
20. Jeon CY, Murray MB. 2008. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS. Med. 5:e152.
21. Kleiber M. 1932. Body size and metabolism. Hilgardia 6:315-353.
22. Kleiber M. 1947. Body size and metabolic rate. Physiol. Rev. 27:511-541.
23. Kruger HS, Puoane T, Senekal M, van der Merwe MT. 2005. Obesity in South Africa: challenges for government and health professionals. Public Health Nutr. 8:491-500. (Pubitemid 41431371)
24. Lee CS, Brater DC, Gambertoglio JG, Benet LZ. 1980. Disposition kinetics of ethambutol in man. J. Pharmacokinet. Biopharm. 8:335-346. (Pubitemid 10025207)
25. Lee CS, Gambertoglio JG, Brater DC, Benet LZ. 1977. Kinetics of oral ethambutol in the normal subject. Clin. Pharmacol. Ther. 22:615-621. (Pubitemid 8225579)
26. Ludden TM, Beal SL, Sheiner LB. 1994. Comparison of the Akaike information criterion, the Schwarz criterion and the F test as guides to model selection. J. Pharmacokinet. Biopharm. 22:431-445.
27. Mandelbrot B. 1967. How long is the coast of Britain? Statistical self-similarity and fractional dimension. Science 156:636-638.
28. Mandelbrot BB. 1982. The fractal geometry of nature. W.H. Freeman and Company, San Francisco, CA.
29. McIlleron H, et al. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177.
30. Nijland HM, et al. 2006. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin. Infect. Dis. 43:848-854. (Pubitemid 44435511)
31. Obesity Task Force. 25 October2005. Global strategy on diet, physical activity and health: obesity and overweight. World Health Organization, Geneva, Switzerland. http://www.who.int/hpr/NPH/docs/gs-obesity.pdf.
32. Ogden CL, Fryar CD, Carroll MD, Flegal KM. 2004. Mean body weight, height, and body mass index, United States 1960-2002. Advance data from vital and health statistics; no. 347. National Center for Health Statistics, Hyattsville, MD.
33. Pasipanodya JG, Hall R, Weis S, Gumbo T. 2009. Fat, fractals, and failure of antituberculosis pharmacotherapy. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr L1-1660.
34. Pasipanodya JG, Weis S, Gumbo T. 2010. Weight not diabetes mellitus predicts failure of anti-tuberculosis therapy in treated tuberculosis patients with concurrent diabetes mellitus. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr A1-059.
35. Peloquin CA, et al. 1999. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob. Agents Chemother. 43:568-572. (Pubitemid 29109520)
36. Srivastava S, et al. 2010. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J. Infect. Dis. 201: 1225-1231.
37. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. 2011. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J. Infect. Dis. 204:1951-1959.
38. Srivastava S, Sherman C, Meek C, Leff R, Gumbo T. 2011. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob. Agents Chemother. 55:5085-5089.
39. Swinburn BA, et al. 2011. The global obesity pandemic: shaped by global drivers and local environments. Lancet 378:804-814.
40. Tanaka et al. 1999. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am. J. Respir. Crit. Care Med. 160: 866-872. (Pubitemid 29442022)
41. Wallace RJ, Jr, et al. 1994. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am. J. Respir. Crit. Care Med. 149:1335-1341.
42. West GB, Brown JH, Enquist BJ. 1997. A general model for the origin of allometric scaling laws in biology. Science 276:122-126. (Pubitemid 27161259)
43. West GB, Brown JH, Enquist BJ. 1999. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284:1677-1679. (Pubitemid 29291379)
44. West GB, et al. 2003. Physiology: why does metabolic rate scale with body size? Nature 421:713. (Pubitemid 36227614)
45. World Health Organization. 2010. Treatment of tuberculosis: guidelines, 4th ed. WHO/HTM/TB/2009.420. 2010. World Health Organization, Geneva, Switzerland.
46. Zhu M, et al. 2004. Pharmacokinetics of ethambutol in children and adults with tuberculosis. Int. J. Tuberc. Lung Dis. 8:1360-1367. (Pubitemid 39611583)